Form 4: BioMarin Executive Cristin Hubbard Reports Stock and Option Grants

Cristin Hubbard, EVP and Chief Commercial Officer of BioMarin Pharmaceutical Inc., reports the acquisition of restricted stock units and stock options.

Summary

• Cristin Hubbard, an executive at BioMarin Pharmaceutical Inc., filed a Form 4 detailing changes in beneficial ownership.
• On May 20, 2024, Hubbard acquired 14,690 shares of common stock and 4,700 shares of common stock as restricted stock units, both at a price of $0.
• Following these transactions, Hubbard directly owns 19,390 shares of common stock.
• Hubbard also acquired options to purchase 33,520 shares of common stock at an exercise price of $77.05, exercisable starting May 20, 2025.
• The options expire on May 19, 2034.
• Tae Sang Yoo, Attorney-in-Fact, signed the report on May 22, 2024.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The sentiment is neither particularly positive nor negative.

Positives

• The acquisition of stock and options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the alignment of management's interests with those of shareholders.

Stakeholder Impact

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders, potentially incentivizing performance that benefits the company and its investors.

Key Dates